Table 10.

Differences in ALSFRS-R scores between Cycle 1 (Baseline) and Cycle 6 (LOCF)

Treatment group	Number of subjects	Adjusted mean change from baseline		Between-group differences in adjusted mean
		LS mean ± SE		LS mean ± SE (95% CI)	p value†
Placebo	66	−7.50 ± 0.66		2.49 ± 0.76 (0.99, 3.98)	p = 0.0013
Edaravone	68	−5.01 ± 0.64

^†Compared between treatment groups using an analysis of variance (ANOVA) with treatment group and three dynamic allocation factors. For patients with missing values at the end of cycle 6, data were imputed by the LOCF method, provided that they had completed at least to cycle 3. ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; CI, confidence interval; LOCF, last observation carried forward; LS, least squares; SE, standard error.